The treatment by using rivastigmine for patients with Alzheimer disease: results of a multicenter,randomized,open-labeled,controlled clinical trial
- VernacularTitle:卡巴拉汀治疗阿尔茨海默病患者的临床研究
- Author:
Yinhua WANG
;
Qingtang CHEN
;
Zhenxin ZHANG
- Publication Type:Journal Article
- Keywords:
Rivastigmine;
Alzheimer disease;
Cholinesterase inhibitors;
Clinical trials
- From:
Chinese Journal of Neurology
2000;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
0 05) The overall incidence of adverse effects was between 12 9% and 28 8% There were no significant differences between these two groups Rivastigmine had no influence on vital signs and laboratory indexes Conclusion Rivastigmine may significantly improve the symptoms of the patient with AD and have a good safety and tolerability,being an ideal choice in treating AD
